The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Vol.
30
No.
39
October 15, 2004Oct 15, 2004
Free
DOWNLOAD THE PDF

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

Also in this 8-page issue: NCI closes its Tobacco Intervention Research Clinic, blaming flat budget, slow accrual.

Hope for FDA authority over tobacco products dies in Congress.

Patients urge Medicare to allow an open formulary for cancer treatment.

Promotions at MSKCC: Fuks heads radiation oncology, Pfister named chief of Head & Neck Medical Oncology Service.

Funding opportunities listed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account